Patent EA-004040-B1 (EA)
Title: Novel derivatives of cyclobuta-indole carboxamide, process for preparing them and pharmaceutical compositions containing them
Inventor: PEGLION JEAN-LOUIS
IPC: A61P9/00
Filed: 2000-12-29
Abstract: 1. Compounds of formula (I): wherein: V represents a single bond or a linear or branched (C1-C6)alkylene chain, M represents a single bond or a linear or branched (C1-C6)alkylene chain, A and E each represents a nitrogen atom or a CH group, but at least one of the two groups A or E represents a nitrogen atom, W represents a group of formula (ia), (ib), (ic), (iia), (iib), (iic), (iid) or (iie), and also may represent a group of formula (iiia), provided that when V represents a single bond and A represents a nitrogen atom, in which groups of formulae (ia), (ib), (ic), (iia), (iib), (iic), (iid), (iie) and (iiia): X represents a carbonyl or a sulphonyl group, R1 represents a hydrogen atom, linear or branched (C1-C6)alkyl group, R2a and R2b, which are the same or different, each independently of the other represents a group selected from a hydrogen atom, a halogen atom, a hydroxy group, a linear or branched (C1-C6)alkoxy group, linear or branched (C1-C6)trihaloalkyl group, a cyano group, a nitro group, phenyl-(C1-C6)alkoxy group, or R2a + R2b, taken together in adjacent positions, represent a group selected from methylenedioxy, 1,2-ethylenedioxy, and 1,3-propylenedioxy, R3 represents phenyl or pyridyl, each of which groups may optionally be substituted by one or more groups, which may be the same or different, selected from among the definitions of R2a. Y represents benzofuran-3-yl or a phenoxy group, linear or branched (C1-C6)alkyl-sulfonyl, their isomers, their hydrates, their solvates and addition salts thereof with a pharmaceutically acceptable acids, with the proviso that: * when V represents a single bond and W represents a group of formulae (ia), (ib) or (ic) wherein R3 represents a phenyl group, then Y cannot represent a 3-indolyl group, * when M represents a single bond and W represents a group of formulae (ia), (ib) or (ic), then if Y represents a bicyclic heteroaryl-B group wherein one of the rings represents a benzene ring the said group Y cannot be joined to M by the said benzene ring, * and when M represents a single bond, V represents an ethylene group and W represents a group of formulae (ia), (ib) or (ic), wherein R3 represents a phenyl group, then Y cannot represent a 1,2-benzisoxazol-3-yl group. 2. Compounds of formula (I) according to claim 1, characterised in that W represents a group of formulae (ia), (ib) or (ic) as defined for formula (I), their isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 3. Compounds of formula (I) according to claim 2, characterised in that R3 represents a phenyl group optionally substituted by a halogen atom, a hydroxy group, a linear or branched (C1-C6)alkoxy group, phenyl(C1-C6)alkoxy group, a nitro group, linear or branched (C1-C6)trihaloalkyl group and a cyano group, X represents a carbonyl group, A represents a nitrogen atom when E represents a CH group, or A represents a CH group when E represents a nitrogen atom, M represents a linear or branched (C1-C4)alkylene chain, their isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 4. Compounds of formula (I) according to claim 3, characterised in that R3 represents a phenyl group optionally substituted by a halogen atom, their isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 5. Compounds of formula (I) according to claim3, characterised in that: * A represents a nitrogen atom and E represents a CH group when Y represents an optionally substituted phenyloxy group, * or A represents a CH group and E represents a nitrogen atom when Y represents a benzofuran-3-yl group, their isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 6. Compounds of formula (I) according to claim 3, characterised in that: *V represents a single bond when Y represents a benzofuran-3-yl group, *or V represents a linear or branched (C1-C4)alkylene chain when Y represents an optionally substituted phenyloxy group, their isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 7. Compounds of formula (I) according to claim 1, characterised in that W represents a group of formulae (iia), (iib), (iic) (iid) or (iie) as defined for formula (I), their isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 8. Compounds of formula (I) according to any one of claims 1 to 7, characterised in that X represents a carbonyl group, R1 represents a hydrogen atom, M represents a linear or branched (C1-C4)alkylene chain, their isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 9. Compounds of formula (I) according to claim 8, characterised in that: * A represents a nitrogen atom and E represents a CH group when Y represents an optionally substituted phenyloxy group, * or A represents a CH group and E represents a nitrogen atom when Y represents a benzofuran-3-yl group, their isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 10. Compounds of formula (I) according to claim 8, characterised in that: *V represents a single bond when Y represents a benzofuran-3-yl group, *or V represents a linear or branched (C1-C4)alkylene chain when Y represents an optionally substituted phenyloxy group, their isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 11. Compounds of formula (I) according to claim 1, characterised in that: W represents a group of formula (iiia) as defined for formula (I), their isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 12. Compounds of formula (I) according to claim 1 which are: -N-{2-[4-(phenoxymethyl)-1-piperidyl]ethyl}-1-indolinecarboxamide, -5-fluoro-N-(2-{4-[2-(4-fluorophenoxy)ethyl]-1-piperidyl}ethyl)-1-indolecarboxamide, -N-{2-[4-(p-fluorophenoxymetyl)-1-piperidyl]ethyl}-1-indolinecarboxamide, -N-{2-[4-(phenoxymethyl)-1-piperidyl]ethyl}-1-indolecarboxamide, their isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 13. Compound of formula (I) according to claim 1 which is 1-(2-{4-[2-(4-fluorophenoxy)ethyl]-1-piperidyl}ethyl)-3-phenyl-2-imidazolidinone, its isomers, hydrates, solvates and addition salts thereof with a pharmaceutically acceptable acids. 14. Pharmaceutical compositions comprising as active ingredient at least one compound of formula (I) according to any one of claims 1 to 13, alone or in combination with one or more inert, non-toxic pharmaceutically acceptable excipients or carriers. 15. Pharmaceutical compositions according to claim 14 comprising at least one active ingredient according to any one of claims 1 to 13 for use as a medicament for the treatment of diseases or pathological conditions in which endothelial dysfunction is known. 16. Pharmaceutical compositions according to claim 14 comprising at least one active ingredient according to any one of claims 1 to 13 for use as a medicament for preventing the development, extension and complications of atherosclerotic lesions, in particular for patients having a vascular risk factor (dyslipidaemia, diabetes, systemic arterial hypertension), for preventing vascular complications after vascular bypass, vascular dilatation, vascular repermeabilisation and heart transplantation or for treating myocardial or peripheral ischaemia, cardiac insufficiency and pulmonary arterial hypertension.